BRAF inhibitors vemurafenib (PLX4032) and dabrafenib improve survival of BRAF-mutant melanoma patients compared to chemotherapy, which lead to FDA approval for this treatment in BRAF-mutant melanoma [8]. Here, BRAF is linked to melanoma.